Martin Mackay, Ph.D.

Dr. Martin Mackay is a member of the Board of Directors of Beeline Medicines and a biotechnology executive with more than 30 years of research and development leadership experience. He currently serves on the Boards of Kailera Therapeutics, Sail Biomedicines, and Charles River Laboratories, where he is the Lead Independent Director. Previously, Dr. Mackay served on the Boards of SpringWorks Therapeutics and Novo Nordisk. Dr. Mackay is a co-founder and Chairman of the Board of Rallybio. Previously, he served as Executive Vice President and Head of Research and Development at Alexion Pharmaceuticals and as President, Research and Development at AstraZeneca. Earlier in his career, Dr. Mackay held senior R&D leadership roles at Pfizer, and began his industry career at Beecham Pharmaceuticals. He earned his Ph.D. in molecular genetics from the University of Edinburgh and a first-class honors degree in microbiology from Heriot-Watt University.